首页> The New England journal of medicine> KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma.

KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma.

导出 OA

翻译打印收藏纠错

第一作者： Katherine N,Cahill

第一单位： From Brigham and Women's Hospital, Harvard Medical School, Boston (K.N.C., H.R.K., J.C., J.L., A.C.-T., D.G., T.M.L., J.A.B., E.I.), and Novartis Institutes for BioMedical Research, Cambridge (S.K.) - both in Massachusetts; Washington University, St. Louis (M.C.); University of Wisconsin, Madison (N.J.); Columbia University Medical Center, New York (E.D.); Cleveland Clinic, Cleveland (S.E.); University of Alabama at Birmingham, Birmingham (J.L.T.); Temple University, Philadelphia (K.S.), and Pennsylvania State University, Hershey (V.M.C.) - both in Pennsylvania; and National Jewish Health, Denver (M.E.W.).

作者： Katherine N,Cahill ^[1] ; Howard R,Katz ^[1] ; Jing,Cui ^[1] ; Juying,Lai ^[1] ; Shamsah,Kazani ^[1] ; Allison,Crosby-Thompson ^[1] ; Denise,Garofalo ^[1] ; Mario,Castro ^[1] ; Nizar,Jarjour ^[1] ; Emily,DiMango ^[1] ; Serpil,Erzurum ^[1] ; Jennifer L,Trevor ^[1] ; Kartik,Shenoy ^[1] ; Vernon M,Chinchilli ^[1] ; Michael E,Wechsler ^[1] ; Tanya M,Laidlaw ^[1] ; Joshua A,Boyce ^[1] ; Elliot,Israel ^[1]

作者单位： From Brigham and Women's Hospital, Harvard Medical School, Boston (K.N.C., H.R.K., J.C., J.L., A.C.-T., D.G., T.M.L., J.A.B., E.I.), and Novartis Institutes for BioMedical Research, Cambridge (S.K.) - both in Massachusetts; Washington University, St. Louis (M.C.); University of Wisconsin, Madison (N.J.); Columbia University Medical Center, New York (E.D.); Cleveland Clinic, Cleveland (S.E.); University of Alabama at Birmingham, Birmingham (J.L.T.); Temple University, Philadelphia (K.S.), and Pennsylvania State University, Hershey (V.M.C.) - both in Pennsylvania; and National Jewish Health, Denver (M.E.W.). ^[1]